Gemcitabine alone or in combination with cisplatin cost effective in NSCLC

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.363, 2002-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus cisplatin for NSCLC

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Gemcitabine + cisplatin for NSCLC: genotype predicts survival

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Aprinocarsen/cisplatin/gemcitabine may have activity in NSCLC

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer

By Lees M.

PharmacoEconomics, Vol. 20, Iss. 5, 2002-01 ,pp. : 325-337

Adis International

Access to resources Recommend Favorite

Erlotinib marginally cost effective for NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 601, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite